Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is back with a new cut showing 6% weight loss in a phase 2a study. Structure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback